Aldeyra Therapeutics Inc (NAS:ALDX)
$ 4.82 -0.08 (-1.63%) Market Cap: 287.03 Mil Enterprise Value: 194.66 Mil PE Ratio: 0 PB Ratio: 3.37 GF Score: 41/100

Aldeyra Therapeutics Inc Call to Report Top-Line Results from the Crossover Clinical Trial of Reproxalap Transcript

Jul 12, 2022 / 12:00PM GMT
Release Date Price: $5.14 (+14.99%)
Operator

Good morning, and welcome to the Aldeyra Therapeutics conference call. (Operator Instructions)

I would now like to hand the conference call over to Bruce Greenberg, Vice President of Finance, Interim Chief Financial Officer and Treasurer. Thank you. Sir, please go ahead.

Bruce Greenberg
Aldeyra Therapeutics, Inc. - VP of Finance, Interim CFO & Treasurer

Thank you, and good morning, everyone. With me are President and Chief Executive Officer, Dr. Todd Brady; and Kelly Mizer, our Vice President of Commercial Strategy and Operations. Joining us on today's call is Dr. John Berdahl, a specialist in diseases of the anterior segment at Vance Thompson Vision and Professor of Ophthalmology at the Stanford School of Medicine.

This morning, we issued a press release reporting top-line results for the Crossover clinical trial of reproxalap for the treatment of dry eye disease. A copy of the press release is available on the Investors & Media section of our website, www.aldeyra.com.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot